GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (LTS:0QKQ) » Definitions » Price-to-Free-Cash-Flow

Relief Therapeutics Holding (LTS:0QKQ) Price-to-Free-Cash-Flow : N/A (As of May. 10, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Relief Therapeutics Holding Price-to-Free-Cash-Flow?

As of today (2025-05-10), Relief Therapeutics Holding's share price is CHF2.23. Relief Therapeutics Holding's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was CHF-0.25. Hence, Relief Therapeutics Holding's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Relief Therapeutics Holding's Price-to-Free-Cash-Flow or its related term are showing as below:

LTS:0QKQ's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 29.03
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Relief Therapeutics Holding's Free Cash Flow per Share for the six months ended in Dec. 2024 was CHF0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was CHF-0.25.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 64.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was -0.80% per year.

During the past 13 years, Relief Therapeutics Holding's highest 3-Year average Free Cash Flow per Share Growth Rate was 69.20% per year. The lowest was -256.90% per year. And the median was 29.50% per year.


Relief Therapeutics Holding Price-to-Free-Cash-Flow Historical Data

The historical data trend for Relief Therapeutics Holding's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Price-to-Free-Cash-Flow Chart

Relief Therapeutics Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Relief Therapeutics Holding Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Relief Therapeutics Holding's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Relief Therapeutics Holding's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Price-to-Free-Cash-Flow falls into.


;
;

Relief Therapeutics Holding Price-to-Free-Cash-Flow Calculation

Relief Therapeutics Holding's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=2.23/-0.246
=N/A

Relief Therapeutics Holding's Share Price of today is CHF2.23.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Relief Therapeutics Holding's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2024 was CHF-0.25.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Relief Therapeutics Holding  (LTS:0QKQ) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Relief Therapeutics Holding Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Geneva, CHE, 1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Relief Therapeutics Holding Headlines

No Headlines